Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis

• Published in: Biomolecules & biomedicine Vol. 21; no. 3; pp. 331 - 338
• Main Authors: Feng, Xu, Xu, En-Shi
• Format: Journal Article
• Language: English
• Published: Bosnia Association of Basic Medical Sciences 01.06.2021; Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
• Subjects: alectinib; ALK; Complications and side effects; Drug therapy; FN1; Genetic aspects; Health aspects; lorlatinib; Lung cancer, Non-small cell; Metalloenzymes; Metastasis; MMPs; Physiological aspects; VIM; China

Most advanced non-small cell lung cancer (NSCLC) patients are accompanied by brain metastasis which is the major cause of increased mortality. The fusion rearrangement of anaplastic lymphoma kinase (ALK) gene is an important feature of brain metastasis in lung cancer. The novel ALK inhibitors alecti...